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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine “Is famciclovir
superior to valacyclovir as a treatment for recurrent genital herpes in reducing outbreak duration
and frequency?”
STUDY DESIGN: This review is based on three double-blind, randomized controlled trials
(RCTs) published in 2006, 2008, and 2009. The studies compared the efficacy and safety of
famciclovir (FCV) vs. valacyclovir (VCV) in the treatment of genital herpes.
DATA SOURCES: All articles used were published in English, in peer-reviewed journals, and
found using PubMed.
OUTCOMES MEASURED: The effectiveness of famciclovir and valacyclovir was evaluated
based on the proportion of patients with aborted lesions, the time to resolutions of lesions of
active infection and all associated symptoms, the time to next reoccurrence, and the proportion of
patients with a recurrence.
RESULTS: All three studies found that there were no significant differences in efficacy or
safety in terms of clinical disease manifestations between FCV and VCV. Median time to
healing of herpes lesions was similar in both groups (4.25 days vs. 4.08 days), and about onethird of patients in both groups experienced aborted lesions. A follow-up study showed similar
times to next recurrence (33.5 days vs. 38 days). Values for evaluating frequency of recurrences
proved to be similar as well, with 34% of the FCV group and 28% of the VCV group
experiencing an outbreak within a 16-week post-treatment period, and the mean number of
recurrences being 0.11 and 0.10, respectively.
CONCLUSIONS: The results of the three RCTs demonstrate that famciclovir is equally
effective compared to valacyclovir, but does not appear to be superior in treating genital herpes.
However, the shorter dosing schedule of famciclovir for herpes recurrence may provide a more
convenient treatment option for some patients, and further comparative studies are warranted to
investigate whether improvements in virologic disease manifestations from previous in vivo
murine studies translate into clinically meaningful results.
KEY WORDS: Valacyclovir, famciclovir, recurrent, genital herpes.
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INTRODUCTION
Genital herpes is a highly contagious sexually transmitted disease most commonly caused
by herpes simplex virus type 2 (HSV-2), although the rate of herpes simplex virus type 1 (HSV1) genital infection has been rising due to the increase in oral-genital transmission. After an
initial HSV-2 infection, over 90% of patients experience a reactivation of latent virus residing in
the cell bodies of neurons at some point in their lives, and about one-third have frequent
outbreaks (>6 per year).1 Although non-lethal and often asymptomatic, recurrent outbreaks as
well as the infections potential to the patient’s sexual partners results in significant psychological
stress to the patient. Social stigma and shame also add to the negative impact on the patient’s
quality of life. 3 While the disease remains incurable, treatment is possible. This paper evaluates
three randomized trials (RCTs) comparing the efficacy and safety of famciclovir vs. valacyclovir
in the episodic treatment of genital herpes.
In the U.S., approximately 17% of adults are seropositive for HSV-2, making it one of the
most common sexually transmitted diseases. Worldwide, the condition has become epidemic and
the prevalence is 30%.1 The cost of incident infections was $1.8 billion in 2000, and projected to
increase to $2.7 billion by 2025 as the incidence and prevalence continues to rise. Projected cost
over the next 25 years is estimated at $61 billion. 5 Approximately 499,655 healthcare visits
related to HSV occurred in 2000, with 2,056,1180 pharmacy claims. While these values clearly
represent the severity of genital herpes as a public health problem, only 9%-50% of infected
individuals are aware of their infection, which results in less healthcare visits than would be
expected. 4
It is unknown as to why some patients never have a subsequent outbreak while others
have severe, continuous outbreaks. Still others may have asymptomatic recurrent reactivation of
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virus. This variability in disease presentation further complicates its management and causes its
transmission to be unpredictable.11 It is known that transmission can occur during active
outbreaks and possibly during latent viral shedding, but there are no methods available to
patients for them to definitively know when they are experiencing viral shedding, and no clear
connection has been made between viral titer level and chance of transmission to a partner, with
only the latter being clinically relevant. 9 Additionally, genital vs. oral and other forms of herpes
infections cannot be differentiated based on seropositivity alone, making detection and screening
a challenge.1 Finally, medical practitioners should be aware of the psychosocial concerns
associated with genital herpes. Decreased self-esteem, anger, depression, social isolation, and
guilt often accompany a new diagnosis. Many patients experience significant distress due to their
perceived lack of control of the disease, sexual and/or social rejection, and the lifelong course of
infectivity. 10
Currently, three oral antivirals are approved for the treatment of genital herpes:
Acyclovir (ACV), valacyclovir (VCV), and famciclovir (FCV). ACV was the first to be
approved in the early 1980s, but its low bioavailability of 10-20% presented a possibility for
drug improvement. FCV, a prodrug of penciclovir (which is structurally similar to ACV), and
VCV, the l-valine ester and prodrug of ACV, were discovered later on to have improved
systemic absorption and longer duration of action. 7 Other treatments include over-the-counter
pain relievers, such as ibuprofen and acetaminophen, and a wide range of alternative therapies,
including but not limited to Echinacea, propolis, Prunella vulgaris, Rozites caperata, warm water
soaks, lysine, baking soda, cornstarch, tea bags, ice, and aloe vera. 11
Only the antiviral medications have been proven to be clinically effective in treating
genital herpes. Most other methods are home-remedies for symptomatic relief and there is
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limited, if any, scientific literature. Treatment with antivirals centers around three approaches:
First occurrence, recurrence, and suppression. Early treatment soon after the first outbreak has
been shown in mice to significantly reduce the possibility of future outbreaks by reducing the
viral load that remains in the neural ganglia. Recurrent outbreaks are best treated within the first
24 hours of prodromal symptoms due to the rapid burst of viral replication during this time.
Various regimens of episodic therapy differing in drug quantity, dosing frequency, and length of
treatment are available, ranging from 1-5 days. 1 Suppressive therapy on a daily basis reduces the
frequency of recurrence and viral shedding.6 While various trials have already demonstrated the
safety and improved efficacy of these antivirals compared to placebo within the three treatment
modalities, few direct comparison RCTs of the antivirals have been performed. 7
OBJECTIVE
The objective of this systematic review is to determine “Is famciclovir superior to
valacyclovir as a treatment for recurrent genital herpes in reducing outbreak duration and
frequency?”
METHODS
Specific selection criteria of three RCTs were used for this selective EBM review. The
population chosen consisted of patients, at least 18 years of age, immunocompetent, with a
history of frequent recurrent genital herpes (>4-6 recurrences per year). The intervention used in
each RCT was FCV as daily and episodic therapy compared to VCV. All of the studies utilized
included several outcomes but for the purpose of this review, the outcomes measured reflected
the efficacy of FCV and VCV in reducing recurrent outbreak duration, frequency, and severity.
Outcomes involving the virologic effects of the drugs were omitted from this review in order to
focus on patient oriented evidence that matters (POEMs).
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Some keywords utilized in the search for RCTs included valacyclovir, famciclovir,
recurrent, and genital herpes. All articles were published in peer-reviewed journals and in the
English language. The author researched the studies through PubMed and selected the articles
based on their relevance to the clinical question and if they included POEMS. Inclusion criteria
included RCTs published after 1996, with patients who had a clinical diagnosis with lab
evidence of HSV, and at least 4 recurrences in the preceding 12 months prior to therapy.
Exclusion criteria included patients under the age of 18, immunocompromised, renal disease,
hepatic impairment, GI malabsorption, and pregnancy. The statistics reported or used in these
studies were RRR, ARR, NNT, RRI, ARI, NNH, p-values, hazard ratios, and CIs. Table 1 shows
the demographics and characteristics of the included studies.
OUTCOMES MEASURED
The outcomes measured were the proportion of patients with aborted lesions, the time to
resolutions of lesions of active infection and all associated symptoms, the time to next
reoccurrence, and the proportion of patients with a recurrence. These outcomes were measured
by using patient self-reports and regular evaluations by clinical assessors throughout the study
period to confirm or deny the presence of outbreak sign/symptoms and monitor lesion healing.
1,2,6

Self-reports consisted of diary entries detailing the exact time of onset, symptoms, and the

lesion stage. Full healing was defined as loss of crust with re-epithelialization of the skin. Those
collecting the patient self-reports and the assessors themselves were blinded to the patients’
group assignment.
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Table 1: Demographics & Characteristics of included studies
Study

Age
(yrs)
18-85
years

Inclusion
Criteria
Patients 18
years or older
with a clinical
diagnosis of
HSV 1 or 2,
lab evidence of
HSV, hx of at
least 4
recurrences of
genital lesions
in the
preceding 12
mo. or prior to
suppressive
therapy

Bodsworth Double 666
2
(2009)
blind
RCT

>18
years
old

Wald6
(2006)

>18
years
old

Patients who
successfully
completed the
Abudalu study
and
experienced a
reoccurrence
of genital
herpes during
the acute phase
of the study
Patients 18
years or older
with a hx of at
least 6
recurrences in
the past year,
or prior to
suppressive
therapy

Abudalu1
(2008)

Type

# Pts.

Double 1179
blind
RCT

Double 320
blind
RCT

Exclusion
W/D Interventions
Criteria
Hx of renal dz, 57
1 tab 1 g
hepatic
famciclovir
impairment, GI
BID x 1 day
malabsorption,
vs. 1 tab 500
immunosuppre
mg
-ssion,
valacyclovir
pregnancy, use
po BID 3
of concomitant
day. Therapy
cimetidine
initiated
and/or
w/in 6 hrs
probenecid
after the
therapy
onset of
prodromal
symptoms
and/or
genital
herpes
Same as
0
Same as
Abudalu
Abudalu

Kidney
32
impairment,
liver dz, HIV,
pregnancy,
receipt of other
investigational
drugs, hx of
resistant HSV
infection,
sensitivity to
nucleoside
analogues

1 tab 250 mg
famciclovir
po BID vs. 1
tab
valacyclovir
500 mg po
qd
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RESULTS
This selective EBM review was performed on three RCTs, all of which performed a
head-to-head comparison of famciclovir vs. valacyclovir in an adult, immunocompetent
population
Time to healing and resolution of symptoms. In the 2008 study by Abudalu et al, single
day FCV (1000 mg bid) was compared to 3-day VCV (500 mg bid) in the episodic treatment of
genital herpes. Both treatment groups exhibited similar time to healing of non-aborted lesions,
4.25 days for patients receiving FCV and 4.08 days for patients receiving VCV, with a median
treatment difference of 0.16 days (p= 0.48; 95% CI= -0.15 to 0.60) and hazard ratio of 1.08 (95%
CI; 0.88-1.32). Time to resolution of all symptoms associated with infection, which included
pain, itching, burning, tingling, and tenderness, were similar as well, with a median of 72.9 hours
for FCV, 72.0 hours for VCV (p=0.75), and hazard ratio of 1.03 (95% CI=0.86-1.24) (Table 2).1
Table 2: Famciclovir vs. valacyclovir on the time to healing of lesions and all related symptoms
(Abudalu et al., 2008)1
Efficacy
No. of
Median days
Median days
No. of
Median hours
Parameter
patients
to healing of
of difference
patients
to resolution.
lesions
in time to
whose
healing
symptom(s)
between
resolved
treatments
Famciclovir
249
4.25
0.16
236
72.9
Valacyclovir
253
4.08
238
72.0
Proportion of aborted lesions. Similar proportions of patients with aborted lesions
following initiation of treatment were found between the two groups (32.7% of the FCV group
and 33.6% of the VCV group). 1
Table 3 displays the treatment effects on the proportion of patients with aborted lesions.
The ARR shows an small increase in non-aborted lesions of the FCV group compared to having
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Table 3: Famciclovir vs. valacyclovir on the proportion of patients experiencing non-aborted
lesions (Abudalu et al., 2008)1
Proportion of
Proportion of
Relative Risk
Absolute Risk
Number needed
VCV patients
FCV patients
Reduction (RRR)
Reduction
to treat (NNT)
with non-aborted with non-aborted
(ARR)
lesions
lesions
EER - CER
EER - CER
1/ARR
CER
0.664
0.673
0.014
0.009
112
non-aborted lesions with FCV treatment compared to VCV. NNT is calculated to determine the
number of patients that need to receive FCV to prevent a bad outcome (non-aborted lesions).
With a positive NNT, this is interpreted as single-day FCV treatment of 112 patients results in
one more person developing non-aborted lesions compared to the VCV control group.
Time to next recurrence. Bodsworth et al. in 2009 was a follow-up study of Abudalu et
al. to assess the long-term effect of episodic treatment on disease progression. 87.6% (324/370)
of the FCV recipients and 89.8% (342/381) of the valacyclovir recipients agreed to participate in
this subsequent study, and they were prohibited from initiating suppressive therapy within the 6months following the healing of lesions. Of these patients, 61.1% of the FCV group and 60.6%
of the VCV group experienced another recurrent outbreak during the follow-up period, with a
mean time to next recurrence from treatment initiation of 33.5 days for FCV and 38.0 days for
VCV (Table 4). 2
Table 4: Time to next recurrence within 6-month follow-up period (Bodsworth et al., 2009)2

Famciclovir
Valacyclovir

No. of
patients who
continued to
the follow-up
period
324
342

No. of patients Median days
with next
to next
recurrence
recurrence
during follow- from treatment
up period
initiation
226
33.5
231
38.0

Median of
differences
(days)

95% CI

-3.00

(-8.00,
2.00)
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Proportion with a recurrence. Suppressive therapy was analyzed in the study by Wald et
al. by comparing 250 mg bid FCV with 500 mg q am VCV for 16 weeks, with primary endpoint
being the proportion of patients that experienced a clinically confirmed recurrence during that
period. The end results were similar between the two groups, with approximately 34% of the
famciclovir group and 28% of the valacyclovir group having a recurrence at some point (Relative
risk/hazard ratio = 1.10; 95% CI = 0.94-1.28). 6
Table 5: Famciclovir vs. valacyclovir on suppression of genital herpes recurrences during 16
weeks of administration (Wald et al., 2006)6
Proportion with
Relative
95% CI
P Value
a clinically
Risk/Hazard
confirmed
Ratio for
recurrence
Famciclovir
Famciclovir
34%
1.10
(0.94-1.28)
P = 0.22
Valacyclovir
28%
Proportion of
VCV patients
having a
recurrence
0.28

Treatment effects on patients with a recurrence
Proportion of
Relative Risk
Absolute Risk
FCV patients
Reduction
Reduction (ARR)
having a
(RRR)
recurrence
EER - CER
EER - CER
CER
0.34
0.21
0.06

Number needed to
treat (NNT)
1/ARR
17

Table 5 summarizes the results and treatment effects of Wald et al. The ARR shows a
small increase in rate of recurrence with the FCV group compared to the VCV group, and RRR
represents the effectiveness of FCV and the relative probability of experiencing a recurrence
with FCV treatment compared to VCV. NNT is calculated to determine the number of patients
that need to receive FCV to prevent a recurrence, interpreted as daily FCV treatment of 17
patients over 16 weeks results in one more person developing a recurrence compared to the VCV
control group.

Feng, Famciclovir, Valacyclovir, and Genital Herpes

9

Exclusions and compliance. All studies utilized consisted of similar inclusion/exclusion
criteria, with a few exceptions. Abudalu et al. prohibited the use of concurrent cimetidine and/or
probenecid therapy due to drug interactions and the possibility of increasing FCV and VCV drug
levels, and only Wald et al. specifically stated that those with a history of HSV resistant to
acyclovir or penciclovir were to be excluded. Both studies also commented on a high rate of
compliance with study medications. For Wald et al., median adherence was 100% and 98% for
the VCV and FCV arm, respectively, while Abudalu et al. reported that 97% of the FCV patients
received the proper 2 doses on day 1 and 92.2% of the VCV patients received all 6 doses over 3
days. 1,6
Safety and Tolerability. Adverse events in all trials were mostly mild to moderate in
intensity, with headaches and nausea being the most common. Rates of AEs were similar
between the two drugs (23.2% for FCV and 22.3% for VCV, NNH = 112, Abudalu et al.) and
consistent with previously established safety profiles. In Abudalu et al., 2 patients in the FCV
arm reported serious AEs of myocardial ischemia and suicide attempt, and 1 patient of the VCV
arm reported polysubstance abuse. Hiatal hernia and chest pain were the only serious AEs
reported by 2 subjects in the VCV treatment group of Wald et al., and both were deemed
unrelated to the study medication. 1,6
Control Event
Rate (CER)
.223

Table 6: Adverse Effects (Abudalu et al., 2008)
Experimental
Relative risk
Absolute risk
Event Rate
increase (RRI)
increase (ARI)
(EER)
EER - CER
EER - CER
CER
.232
0.0404
0.009

Number needed
to harm (NNH)
1/ARR
112

Table 6 outlines the treatment effects on AEs. A small RRI, ARI, and large NNH relative
to the study indicate that AEs for both drugs were comparable.
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DISCUSSION
While the trials by Wald et al. showed no major difference in time to first clinically
confirmed recurrence, it did find a significant difference in time to first virologically confirmed
recurrence and percentage of days with viral shedding, with VCV performing better than FCV. 6
However, a clinical connection failed to be made with this data and thus was not be included in
this SR. This limitation exists across many studies due to the fact that viral load has been shown
to exhibit a complex relationship with disease pathogenesis and transmission. With transmission
being a big concern for many patients, this relationship needs to be further explored. 10
Likelihood of transmission is not based on viral titer alone, still occurs despite daily suppressive
therapy, and may be affected by other factors such as site/size of area of exposure, viral strain,
inoculum size, physiochemical barriers, innate immunity, and genetics. 9 The three trials
analyzed in this review all showed similar efficacy between VCV and FCV based on clinically
measurable factors, but Wald et al. and others have shown advantages to certain antivirals based
on viral factors. 6,7 With FCV exhibiting a longer intracellular half-life, whereas VCV
irreversibly terminates viral DNA replication, these subtle differences should encourage
continued exploration on possible clinical benefits.7 Additionally, the release of the results from
Wald et al. were delayed for 7 years by the pharmaceutical companies, possibly in an attempt to
suppress unfavorable data against FCV. 6,7
The other limitation that remains in this SR is that Bodsworth et al. failed to include a
placebo arm. Thus, assessments of short-course therapy on natural history of HSV could not be
made. 2
Acyclovir as an intervention was not considered in this review for a number of reasons.
First of all, numerous RCTs have performed pair-wise comparisons of ACV with FCV and VCV,
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already establishing comparable efficacy of the latter two with the former. Second, ACV’s low
bioavailability is seen as a disadvantage compared to the other antivirals, especially with VCV
being converted to ACV once systemically absorbed with higher serum concentrations. Finally,
fewer head-to-head comparisons of FCV with VCV have been published, which was the desired
focus of this review. 7
While both FCV and VCV have already been established as relatively safe drugs, it
should be made aware that one known case of VCV-induced psychosis and mania was reported
in 2009 in an adolescent female with no previous psych history. Previously, similar findings have
only been limited to the elderly and immunocompromised with ACV and penciclovir. This
represents an incredibly rare but serious adverse effect. 8
CONCLUSION
Based on this review, famciclovir is not superior to valacyclovir as a treatment for genital
herpes in reducing outbreak frequency and duration. However, it appears to at least be equally
effective, and the shorter single-day dosing schedule of FCV for herpes recurrence may provide
a more convenient treatment option for some patients. Further comparative studies are warranted
to investigate whether improvements in virologic disease manifestations from previous in vivo
murine studies translate into clinically meaningful results. 7 In addition, variations in dosing
regimens should be considered. These explorations could potentially have huge implications in
regards to herpes patients’ improvements in quality of life.
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